RT Journal Article
SR Electronic
T1 EXTENDING THE SUSCEPTIBLE-EXPOSED-INFECTED-REMOVED (SEIR) MODEL TO HANDLE THE HIGH <em>fa</em>LSE <em>n</em>EGATIVE RATE AND <em>sy</em>MPTOM-BASED ADMINISTRATION OF COVID-19 DIAGNOSTIC TESTS: <em>SEIR-fansy</em>
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.24.20200238
DO 10.1101/2020.09.24.20200238
A1 Ritwik Bhaduri
A1 Ritoban Kundu
A1 Soumik Purkayastha
A1 Michael Kleinsasser
A1 Lauren J. Beesley
A1 Bhramar Mukherjee
YR 2020
UL http://medrxiv.org/content/early/2020/09/25/2020.09.24.20200238.abstract
AB The false negative rate of the diagnostic RT-PCR test for SARS-CoV-2 has been reported to be substantially high. Due to limited availability of testing, only a non-random subset of the population can get tested. Hence, the reported test counts are subject to a large degree of selection bias. We consider an extension of the Susceptible-Exposed-Infected-Removed (SEIR) model under both selection bias and misclassification. We derive closed form expression for the basic reproduction number under such data anomalies using the next generation matrix method. We conduct extensive simulation studies to quantify the effect of misclassification and selection on the resultant estimation and prediction of future case counts. Finally we apply the methods to reported case-death-recovery count data from India, a nation with more than 5 million cases reported over the last seven months. We show that correcting for misclassification and selection can lead to more accurate prediction of case-counts (and death counts) using the observed data as a beta tester. The model also provides an estimate of undetected infections and thus an undereporting factor. For India, the estimated underreporting factor for cases is around 21 and for deaths is around 6. We develop an R-package SEIR-fansy for broader dissemination of the methods.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research is supported by the Michigan Institute of Data Science (MIDAS), Precision Health Initiative and RogelScholar Fund at the University of Michigan. Bhramar Mukherjee's research is supported by NSF DMS 1712933 and CA 046592.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode for R package available: https://github.com/umich-biostatistics/SEIRfansy https://github.com/umich-biostatistics/SEIRfansy